1. Pink Sheet

Stakeholders To ‘Voice Concerns’ On Future Guidelines For Canada’s Controversial Pricing Mechanism

 
• By Neena Brizmohun

In-person and virtual roundtables next month will let pharma companies have their say on the development of new guidelines relating to the Patented Medicine Prices Review Board’s contentious new pricing method.

A consultation relating to drug pricing in Canada has been launched • Source: Shutterstock

The Patented Medicine Prices Review Board in Canada has launched the first phase of consultations on the development of new guidelines relating to its contentious drug pricing mechanism.

It has invited stakeholders to participate in policy roundtables scheduled for 5 December (English session) and 6 December (French session),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Canada

More from North America

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.